Literature DB >> 11771647

Molecular mechanisms of gating and drug block of sodium channels.

William A Catterall1.   

Abstract

Voltage-gated Na+ channels are composed of an alpha subunit of 260 kDa associated with beta subunits of 33-36 kDa. Alpha subunits have four homologous domains (I to IV) containing six transmembrane alpha helices (S1-S6). The S4 segments serve as voltage sensors and move outward to initiate activation. The S5 and S6 segments and the short membrane-associated loops between them form the pore. Fast inactivation is mediated by closure of an inactivation gate formed by the intracellular loop between domains III and IV. The 3-D structure of the inactivation gate has been determined bv NMR spectroscopy, revealing the conformation of the pore-blocking IFM motif. Peptide scorpion toxins that alter gating of Na+ channels bind to the extracellular ends of the IIS4 and IVS4 segments, trap them in either an activated or non-activated position, and thereby selectively alter channel activation or inactivation. Voltage sensor-trapping may be a general mechanism of toxin action on voltage-gated ion channels. Local anaesthetics block the pore of Na+ channels by binding to a receptor site in segment S6 in domains III and IV. Anticonvulsants and antiarrhythmic drugs also interact with this site. A high-affinity Na+ channel blocker has recently been developed with this site as its target. The emerging knowledge of the molecular mechanisms of Na+ channel gating and drug block may allow development of novel therapeutics for epilepsy, cardiac arrhythmia and persistent pain syndromes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11771647

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  51 in total

1.  Cyclic nucleotide-gated channel block by hydrolysis-resistant tetracaine derivatives.

Authors:  Adriana L Andrade; Kenneth Melich; G Gregory Whatley; Sarah R Kirk; Jeffrey W Karpen
Journal:  J Med Chem       Date:  2011-06-14       Impact factor: 7.446

2.  Halogen substituents on the aromatic moiety of the tetracaine scaffold improve potency of cyclic nucleotide-gated channel block.

Authors:  Sarah R Kirk; Adriana L Andrade; Kenneth Melich; Evan P Jackson; Elysia Cuellar; Jeffrey W Karpen
Journal:  Bioorg Med Chem Lett       Date:  2011-08-27       Impact factor: 2.823

Review 3.  The ß subunit of voltage-gated Ca2+ channels.

Authors:  Zafir Buraei; Jian Yang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

4.  Modifications to the tetracaine scaffold produce cyclic nucleotide-gated channel blockers with widely varying efficacies.

Authors:  Timothy Strassmaier; Ramalinga Uma; Ambarish S Ghatpande; Tapasree Bandyopadhyay; Michelle Schaffer; John Witte; Patrick G McDougal; R Lane Brown; Jeffrey W Karpen
Journal:  J Med Chem       Date:  2005-09-08       Impact factor: 7.446

5.  Structural determinants of drugs acting on the Nav1.8 channel.

Authors:  Liam E Browne; Frank E Blaney; Shahnaz P Yusaf; Jeff J Clare; Dennis Wray
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

6.  BACE1 regulates voltage-gated sodium channels and neuronal activity.

Authors:  Doo Yeon Kim; Bryce W Carey; Haibin Wang; Laura A M Ingano; Alexander M Binshtok; Mary H Wertz; Warren H Pettingell; Ping He; Virginia M-Y Lee; Clifford J Woolf; Dora M Kovacs
Journal:  Nat Cell Biol       Date:  2007-06-18       Impact factor: 28.824

Review 7.  The pharmacology of cyclic nucleotide-gated channels: emerging from the darkness.

Authors:  R Lane Brown; Timothy Strassmaier; James D Brady; Jeffrey W Karpen
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

8.  Modulation of sodium channel inactivation gating by a novel lactam: implications for seizure suppression in chronic limbic epilepsy.

Authors:  Paulianda J Jones; Ellen C Merrick; Timothy W Batts; Nicholas J Hargus; Yuesheng Wang; James P Stables; Edward H Bertram; Milton L Brown; Manoj K Patel
Journal:  J Pharmacol Exp Ther       Date:  2008-10-24       Impact factor: 4.030

9.  Osteoarthritis pain has a significant neuropathic component: an exploratory in vivo patient model.

Authors:  Rui V Duarte; Jon H Raphael; Theodoros Dimitroulas; Elizabeth Sparkes; Jane L Southall; Robert L Ashford; George D Kitas
Journal:  Rheumatol Int       Date:  2013-11-10       Impact factor: 2.631

10.  Focal and abnormally persistent paralysis associated with congenital paramyotonia.

Authors:  Armelle Magot; Albert David; Damien Sternberg; Yann Péréon
Journal:  BMJ Case Rep       Date:  2014-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.